Novo Nordisk A/S – Reduction of the share capital
Bagsværd, Denmark, 27 April 2022 – At Novo Nordisk’s Annual General Meeting on 24 March 2022, it was decided to reduce the company’s B share capital from DKK 354,512,800 to DKK 348,512,800 by cancellation of part of the company’s portfolio of own B shares equal to a nominal value of DKK 6,000,000 divided into 30,000,000 B shares of DKK 0.20 each.
Today, Novo Nordisk has registered the implementation of the reduction of the share capital with the Danish Business Authority and cancelled B shares at a nominal value of DKK 6,000,000. After the reduction of the share capital, the company’s share capital is nominally DKK 456,000,000, which is divided into an A share capital of nominally DKK 107,487,200 and a B share capital of nominally DKK 348,512,800.
The reduction of the share capital will not affect Novo Nordisk’s share repurchase programme which will continue as previously announced.
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 47,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com,Facebook, Twitter, LinkedIn, and YouTube.
Further information
| Media: | ||
| Ambre Brown Morley | +45 3079 9289 | abmo@novonordisk.com |
| Natalia Salomao Abrahao (US) | +1 848 304 1027 | niaa@novonordisk.com |
| Investors: | ||
| Daniel Muusmann Bohsen | +45 3075 2175 | dabo@novonordisk.com |
| Ann Søndermølle Rendbæk | +45 3075 2253 | arnd@novonordisk.com |
| David Heiberg Landsted | +45 3077 6915 | dhel@novonordisk.com |
| Jacob Martin Wiborg Rode | +45 3075 5956 | jrde@novonordisk.com |
| Mark Joseph Root (US) | +1 848 213 3219 | mjhr@novonordisk.com |
Company announcement No 31 /2022
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
NEXEN Tire hosts ‘2024 Purple Summit Korea’19.4.2024 09:00:00 CEST | Press release
Carried out sixth hospitality program inviting 60 global partners and executives from around the world SEOUL, South Korea, April 19, 2024 (GLOBE NEWSWIRE) -- NEXEN Tire, a leading global tire manufacturer, today announced that it hosted the 2024 Purple Summit Korea hospitality event, which took place in Korea for the first time from April 16 to 19. The event featured 60 global partners and executives from all over the world, as well as NEXEN Tire representatives. Since 2016, NEXEN Tire has hosted the Purple Summit, an integrated hospitality and marketing program, that aims to foster and strengthen relationships while also increasing the company's global market presence. Throughout the summit, attendees visited the company’s cutting-edge tire plant located in Changnyeong, as well as The NEXEN UniverCity, NEXEN Tire’s central R&D hub. Not only that, but the tire maker invited KLPGA players from the NEXEN-St. Nine Masters event to play golf with guests and tour Busan, Korea’s second large
Fujifilm Healthcare Europe launches lifelike ESD training simulator EndoGel19.4.2024 09:00:00 CEST | Press release
RATINGEN, Germany, April 19, 2024 (GLOBE NEWSWIRE) -- FUJIFILM Healthcare Europe GmbH is pleased to announce the launch of EndoGel, a training model designed for performing Endoscopic Submucosal Dissection (ESD) and Peroral Endoscopic Myotomy (POEM) procedures. This innovative simulator, available in two versions - EndoGel for ESD and EndoGel for ESD/POEM - represents a significant advance in endoscopic training. This simulator aims to improve the skills of endoscopy professionals across Europe and ultimately improve patient outcomes. EndoGel simulates the texture of human tissue involved in ESD and POEM procedures, providing clinicians with a life-like simulation experience. With this unique and innovative training model, endoscopy professionals can benefit from the ability to - practice marking and injecting, - performing circumferential incisions, - performing submucosal dissection, myotomy and clipping. EndoGel is compatible with a wide range of medical devices used in ESD and POEM
NOTICE TO THE ANNUAL GENERAL MEETING OF QPR SOFTWARE PLC19.4.2024 09:00:00 CEST | Press release
QPR SOFTWARE PLC STOCK EXCHANGE RELEASE 19 APRIL 2024 AT 10 A.M. EET NOTICE TO THE ANNUAL GENERAL MEETING OF QPR SOFTWARE PLC Notice is hereby given to the shareholders of QPR Software Plc (“QPR” or the “Company”) that the Annual General Meeting (the “General Meeting”) will be held on Wednesday May 15, 2024, starting at 2:30 p.m. (EEST) at the Company's headquarters at Huopalahdentie 24, 00350 Helsinki, Finland. The reception of shareholders who have registered for the meeting and serving of coffee prior to the meeting will start at 2:00 p.m. (EEST). Matters on the agenda of the General Meeting Opening of the General Meeting Matters of order for the General Meeting Election of a person to scrutinize the minutes and a person to supervise the counting of votes Recording the legality of the meeting Recording the attendance at the meeting and adoption of the list of votes Presentation of the Financial Statements, the report of the Board of Directors and the Auditor’s Report for the year 20
Danske Bank A/S, ledende medarbejderes transaktioner19.4.2024 08:58:55 CEST | pressemeddelelse
19. april 2024 Indberetning nr. 39/2024 Ændring i aktiebesiddelser hos Danske Banks indberetningspligtige i henhold til EU-forordningen om markedsmisbrug I forbindelse med Danske Bank A/S’ aktietilbagekøbsprogram sælger APMH Invest A/S løbende aktier i Danske Bank A/S pro rata. For yderligere detaljer henvises til de vedhæftede skemaer, hvori transaktioner udført af personer med ledelsesansvar og personer med nær tilknytning til disse skal indberettes og offentliggøres. Kontakt: Stefan Singh Kailay, Head of Media Relations, tel. +45 45 14 14 00 Vedhæftet fil APMH Invest A_S - salg - 2024.04.18
Danske Bank A/S, transactions by persons discharging managerial responsibilities19.4.2024 08:58:55 CEST | Press release
19 April 2024 Notification no. 39/2024 Transactions made by persons obliged to report transactions to the Danish FSA and Nasdaq Copenhagen, cf. the EU Market Abuse Regulation. In connection with the share buy-back program in Danske Bank A/S, APMH Invest A/S continuously sells shares pro rata. For further details, please find the attached templates for notifications and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them. Contact: Stefan Singh Kailay, Head of Media Relations, tel. +45 45 14 14 00 Attachment APMH Invest AS - sale - 2024.04.18